JP7795466B2 - モノアシルグリセロールリパーゼ調節因子 - Google Patents

モノアシルグリセロールリパーゼ調節因子

Info

Publication number
JP7795466B2
JP7795466B2 JP2022548400A JP2022548400A JP7795466B2 JP 7795466 B2 JP7795466 B2 JP 7795466B2 JP 2022548400 A JP2022548400 A JP 2022548400A JP 2022548400 A JP2022548400 A JP 2022548400A JP 7795466 B2 JP7795466 B2 JP 7795466B2
Authority
JP
Japan
Prior art keywords
azabicyclo
azaspiro
carbonyl
octan
oxa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022548400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512729A (ja
JP2023512729A5 (cg-RX-API-DMAC7.html
Inventor
ケー. アメリクス,マイケル
ビー. ベリー,シンシア
ガルシア-レイナガ,パブロ
ゴ ラフォルテザ,ブライアン
ティー. リアング,ジミー
Original Assignee
ヤンセン ファーマシューティカ エヌ.ベー.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ.ベー. filed Critical ヤンセン ファーマシューティカ エヌ.ベー.
Publication of JP2023512729A publication Critical patent/JP2023512729A/ja
Publication of JP2023512729A5 publication Critical patent/JP2023512729A5/ja
Application granted granted Critical
Publication of JP7795466B2 publication Critical patent/JP7795466B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022548400A 2020-02-10 2021-02-09 モノアシルグリセロールリパーゼ調節因子 Active JP7795466B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062972484P 2020-02-10 2020-02-10
US62/972,484 2020-02-10
PCT/EP2021/053062 WO2021160602A1 (en) 2020-02-10 2021-02-09 Monoacylglycerol lipase modulators

Publications (3)

Publication Number Publication Date
JP2023512729A JP2023512729A (ja) 2023-03-28
JP2023512729A5 JP2023512729A5 (cg-RX-API-DMAC7.html) 2024-02-20
JP7795466B2 true JP7795466B2 (ja) 2026-01-07

Family

ID=74595268

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548400A Active JP7795466B2 (ja) 2020-02-10 2021-02-09 モノアシルグリセロールリパーゼ調節因子

Country Status (23)

Country Link
US (2) US11708359B2 (cg-RX-API-DMAC7.html)
EP (1) EP4103557B1 (cg-RX-API-DMAC7.html)
JP (1) JP7795466B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220140581A (cg-RX-API-DMAC7.html)
CN (1) CN115066422B (cg-RX-API-DMAC7.html)
AR (1) AR121296A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021220539A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022015116A2 (cg-RX-API-DMAC7.html)
CA (1) CA3169988A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002136A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022011275A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220376A (cg-RX-API-DMAC7.html)
DO (1) DOP2022000162A (cg-RX-API-DMAC7.html)
EC (1) ECSP22062460A (cg-RX-API-DMAC7.html)
ES (1) ES3065721T3 (cg-RX-API-DMAC7.html)
IL (1) IL295447A (cg-RX-API-DMAC7.html)
JO (1) JOP20220180A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022009804A (cg-RX-API-DMAC7.html)
PE (1) PE20221576A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552019A1 (cg-RX-API-DMAC7.html)
TW (1) TW202140465A (cg-RX-API-DMAC7.html)
UY (1) UY39066A (cg-RX-API-DMAC7.html)
WO (1) WO2021160602A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20221576A1 (es) 2020-02-10 2022-10-06 Janssen Pharmaceutica Nv Moduladores de la monoacilglicerol lipasa
KR20220158008A (ko) 2020-03-26 2022-11-29 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제로서의 아자스피로사이클
CA3176113A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Aminocyclobutanes as monoacylglycerol lipase modulators
CA3177058A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Aryl piperidines as monoacylglycerol lipase modulators
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
EP4384165B1 (en) 2021-08-09 2025-07-09 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators for use in autism spectrum disorders
IL313987A (en) 2021-12-29 2024-08-01 Psy Therapeutics Inc Inhibiting monoacylglycerol lipase (magl)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014528428A (ja) 2011-09-30 2014-10-27 ヤンセン ファーマシューティカ エヌ.ベー. 代謝症及び関連障害の治療のためのモノアシルグリセロールリパーゼ阻害剤
WO2018020263A1 (en) 2016-07-29 2018-02-01 Autifony Therapeutics Limited Cyclobutane derivatives as modulators of voltage-gated potassium channels
WO2019065791A1 (ja) 2017-09-29 2019-04-04 武田薬品工業株式会社 複素環化合物
JP2019510026A (ja) 2016-03-31 2019-04-11 武田薬品工業株式会社 複素環化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05000945A (es) 2002-07-25 2005-05-16 Pharmacia Italia Spa Biciclo-pirazoles activos como inhibidores de la cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
WO2017170830A1 (ja) 2016-03-31 2017-10-05 武田薬品工業株式会社 複素環化合物
CN112272670B (zh) 2019-04-16 2023-12-12 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
PE20221576A1 (es) 2020-02-10 2022-10-06 Janssen Pharmaceutica Nv Moduladores de la monoacilglicerol lipasa
KR20220158008A (ko) 2020-03-26 2022-11-29 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제로서의 아자스피로사이클
CA3176113A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Aminocyclobutanes as monoacylglycerol lipase modulators
CA3177058A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Aryl piperidines as monoacylglycerol lipase modulators

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014528428A (ja) 2011-09-30 2014-10-27 ヤンセン ファーマシューティカ エヌ.ベー. 代謝症及び関連障害の治療のためのモノアシルグリセロールリパーゼ阻害剤
JP2019510026A (ja) 2016-03-31 2019-04-11 武田薬品工業株式会社 複素環化合物
WO2018020263A1 (en) 2016-07-29 2018-02-01 Autifony Therapeutics Limited Cyclobutane derivatives as modulators of voltage-gated potassium channels
WO2019065791A1 (ja) 2017-09-29 2019-04-04 武田薬品工業株式会社 複素環化合物

Also Published As

Publication number Publication date
ECSP22062460A (es) 2022-11-30
UY39066A (es) 2021-08-31
EP4103557C0 (en) 2026-02-18
IL295447A (en) 2022-10-01
CN115066422A (zh) 2022-09-16
KR20220140581A (ko) 2022-10-18
BR112022015116A2 (pt) 2022-09-27
US20230382902A1 (en) 2023-11-30
TW202140465A (zh) 2021-11-01
CN115066422B (zh) 2024-11-22
MX2022009804A (es) 2022-09-02
JOP20220180A1 (ar) 2023-01-30
US20210253565A1 (en) 2021-08-19
PE20221576A1 (es) 2022-10-06
ES3065721T3 (en) 2026-05-07
CL2022002136A1 (es) 2023-02-03
EP4103557A1 (en) 2022-12-21
CA3169988A1 (en) 2021-08-19
AR121296A1 (es) 2022-05-04
CR20220376A (es) 2022-09-16
JP2023512729A (ja) 2023-03-28
CO2022011275A2 (es) 2022-08-30
WO2021160602A1 (en) 2021-08-19
PH12022552019A1 (en) 2023-11-29
DOP2022000162A (es) 2022-10-31
EP4103557B1 (en) 2026-02-18
US11708359B2 (en) 2023-07-25
AU2021220539A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
JP7777083B2 (ja) モノアシルグリセロールリパーゼ調節因子としてのアザスピロ環化合物
CN115066422B (zh) 单酰基甘油脂肪酶调节剂
JP7729832B2 (ja) モノアシルグリセロールリパーゼ調節因子としてのアリールピペリジン
JP7729831B2 (ja) モノアシルグリセロールリパーゼ調節因子としてのアミノシクロブタン
US12502378B2 (en) Monoacylglycerol lipase modulators for use in autism spectrum disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250930

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251125

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251219

R150 Certificate of patent or registration of utility model

Ref document number: 7795466

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150